TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06381154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Undergo EUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo lymph node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05470361

Intervention type: PROCEDURE
Intervention: stellate ganglion block (SGB)
Description: The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
Study: NCT06381154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo intratumoral photoradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT and PET/MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Given IV
Study: NCT04946019

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Unity-based MR-Linac guided FSRT
Description: The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
Study: NCT05854615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells
Description: • Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
Study: NCT05462288

Intervention type: DEVICE
Intervention: Entia Liberty
Description: Home monitoring blood analyser
Study: NCT06140914

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics, miRNA studies and studies of blood cells from blood samples
Description: This is an observational study where we follow patients and save blood samples and biopsies for analysis as described above.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics, miRNA studies and studies of blood cells from blood samples
Description: This is an observational study where we follow patients and save blood samples and biopsies for analysis as described above.
Study: NCT06479122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1g acetaminophen is administered during skin closure (end of operation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Ibuprofen
Description: A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1g acetaminophen is administered 6 hours after the first administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Ibuprofen
Description: A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.
Study: NCT04903847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
Description: Two-drug therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
Description: Three-drug therapy
Study: NCT06596317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Description: Patients will undergo chromoendoscopy with spraying indigo carmine.
Study: NCT05957445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active continuous Theta Burst Stimulation
Description: Each patient will receive a series of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, and subsequently a 600-pulse cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham continuous Theta Burst Stimulation
Description: Each patient will receive a series of stimulation sequences，including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, and subsequently a 600-pulse sham cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
Study: NCT05268822

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Movement control exercise with or without specific breathing techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Movement control exercise with or without specific breathing techniques
Study: NCT06509945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: allogeneic peripheral blood stem cell transplantation
Description: Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.
Study: NCT05259306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insightec Exablate Neuro MR-guided focused ultrasound transducer
Description: This study will be utilizing the Insightec Exablate Neuro MR-guided focused ultrasound transducer to deliver low-intensity ultrasonic energy precisely and safely to the target region of the brain. MRgFUS has been FDA approved at high-intensity to treat essential tremor and Parkinson's disease associated tremor. Device premarket approval number (PMA) is P150038, and FDA approval notice was July 11, 2016. This study will be using this device not to make any lesions in the brain (as it is currently FDA approved), but instead to use the precision and non-invasive nature of the device to target the MD thalamus region of the brain at intensities currently approved by the FDA for transcranial ultrasound.
Study: NCT04790851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX+IIV4; COVAX+PPV23
Description: 1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVAX only (1st and 2nd dose)
Description: 1st dose: COVAX only; 2nd dose: COVAX only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IIV4 for the 1st dose and PPV23 for the 2nd dose
Description: 1st dose: IIV4 only; 2nd dose: PPV23 only
Study: NCT06596317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy
Description: Patients will undergo conventional colonoscopy.
Study: NCT06588166

Intervention type: DIAGNOSTIC_TEST
Intervention: Gut microbiome testing
Description: Gut microbiome testing for the characterization of the patient gut microbiome
Study: NCT06712849

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Random Noise Stimulation
Description: Sham transcranial random noise stimulation will be applied over the primary visual cortex (area V1) with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2.0 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 40 minutes.
Study: NCT05188898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MINSD and Hyaluronic acid
Description: After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, a hyaluronic acid-based gel will be applied to the intraosseous periodontal pockets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MINSD
Description: Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
Study: NCT04270656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Description: 5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-injection treatment ( MDI ).
Description: Corresponds to an outpatient visit if the patient is randomized into the multi-injection group
Study: NCT06712849

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Transcranial Random Noise Stimulation
Description: Non-invasive brain stimulation will involve the use of high-frequency transcranial random noise stimulation (100-640 Hz) to apply a 2.0 milliamp current over the primary visual cortex (area V1) for approximately 40 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
Study: NCT06729931

Intervention type: DIAGNOSTIC_TEST
Intervention: Pleural Fluid Quantitative C-Reactive Protein (Q-CRP) Measurement
Description: The intervention involves the measurement of Quantitative C-Reactive Protein (Q-CRP) levels in pleural fluid obtained from patients presenting with lymphocytic exudative pleural effusion. The Q-CRP test is performed using standardized laboratory methods to quantitatively analyze CRP levels, which are then compared between patients with confirmed tuberculous pleural effusion and those with malignant pleural effusion. This diagnostic approach aims to evaluate the efficacy of pleural fluid Q-CRP as a biomarker to differentiate between these two conditions. No therapeutic or invasive interventions are introduced as part of this study beyond routine diagnostic procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pleural Fluid Quantitative C-Reactive Protein (Q-CRP) Measurement
Description: The intervention involves the measurement of Quantitative C-Reactive Protein (Q-CRP) levels in pleural fluid obtained from patients presenting with lymphocytic exudative pleural effusion. The Q-CRP test is performed using standardized laboratory methods to quantitatively analyze CRP levels, which are then compared between patients with confirmed tuberculous pleural effusion and those with malignant pleural effusion. This diagnostic approach aims to evaluate the efficacy of pleural fluid Q-CRP as a biomarker to differentiate between these two conditions. No therapeutic or invasive interventions are introduced as part of this study beyond routine diagnostic procedures.
Study: NCT06646939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PT and OT with a simulated environment
Description: Upon admission to the inpatient rehabilitation unit, participants will undergo a physical and occupational therapy evaluation. The evaluations will include the outcome measures chosen to track for this study (10-meter walk test and Quality Indicators). If a patient meets inclusion/exclusion criteria, informed written consent will be obtained. Throughout the patient's stay, therapists will have the opportunity to perform community integration treatments using the simulated environment. This could include activities such as negotiating a curb, crossing a street, or shopping at a marketplace. The therapist will document the amount of time (units billed) spent performing these interventions. The research investigators will not act as a patient's therapist throughout their admission.
Study: NCT05950776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-S
Description: Vaccination with MVA-SARS-2-S

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-S
Description: Vaccination with MVA-SARS-2-S

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05130502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam roller
Description: The investigators use Foam roller to 3 muscle groups per leg then conduct a dynamic warm up program and conduct performance tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: The investigators use Kinesiotape to 3 muscle groups per leg, wait 45 minutes for bring out the effects then conduct a dynamic warm up program and conduct performance tests
Study: NCT06730893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: share decision aids
Description: card news and videos related to general knowledge and treatment of low-risk thyroid cancer
Study: NCT06731660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education with personalized performance feedback
Description: Education about proper otitis media diagnosis following criteria from the American Academy of Pediatrics with personalized performance feedback on otitis media diagnosis and treatment rates delivered via email

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education with personalized performance feedback
Description: Education about proper otitis media diagnosis following criteria from the American Academy of Pediatrics with personalized performance feedback on otitis media diagnosis and treatment rates delivered via email

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of digital otoscope
Description: Use of the Wispr digital otoscope to diagnose otitis media in place of a traditional visual otoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of digital otoscope
Description: Use of the Wispr digital otoscope to diagnose otitis media in place of a traditional visual otoscope
Study: NCT06729970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline/Trospium Chloride
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline/Trospium Chloride
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline/Trospium Chloride
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline/Trospium Chloride
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Specified dose on specified days
Study: NCT05230095

Intervention type: BEHAVIORAL
Intervention: social cognition tests
Description: The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene.~Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery.~Healthy volunteers will be evaluated only one time.

Intervention type: BEHAVIORAL
Intervention: social cognition tests
Description: The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene.~Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery.~Healthy volunteers will be evaluated only one time.

Intervention type: BEHAVIORAL
Intervention: Quality of life self-questionnaire
Description: Quality of life will be assessed using a self-administered questionnaire in the patients group only.
Study: NCT05764577

Intervention type: PROCEDURE
Intervention: DIEP flap surgery
Description: Removal off the DIEP flap followed by closure of the rectus sheath and abdominal skin.
Study: NCT05261230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vedic Counselling
Description: Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week sessions were provided on one to one bases on personalised approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
Study: NCT05712655

Intervention type: OTHER
Intervention: Measurement of bilateral electromyographic activity of Masseter and Anterior Temporalis muscles.
Description: Assessment was done by surface electromyography (sEMG) device.

Intervention type: OTHER
Intervention: Measurement of bilateral electromyographic activity of Masseter and Anterior Temporalis muscles.
Description: Assessment was done by surface electromyography (sEMG) device.
Study: NCT06006897

Intervention type: OTHER
Intervention: Physical Evaluations of post-COVID-19 individuals
Description: In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis with post-COVID-19 individuals. The data to be obtained from all these evaluations will be collected from the individuals at one time and over a period of approximately 1 hour at the most. Step count tracking with pedometer will be done for each individual for 3 days.

Intervention type: OTHER
Intervention: Physical evaluations of non-post-COVID-19 individuals
Description: In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis without post-COVID-19 individuals.
Study: NCT06729970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Specified dose on specified days
Study: NCT06730256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells Infusion chimeric antigen receptor T cells
Description: CAR-T cells Infusion chimeric antigen receptor T cells
Study: NCT06731361

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Systematic multidisciplinary medication review + ACP (SMMR+)
Description: The intervention is a training in medication assessment. The goal is to align prescription with the treatment goals of nursing home patients which are set in advance care planning conversations. The training consists of 2 components:~1. Medication assessment with the use of the ReNeWAL criteria (adjusted STOPP/START criteria, tailored to nursing home patients with a limited life expectancy)~2. Advance care planning component. Discussing medication in line with the treatment goals set in advance care planning conversations.~Healthcare professionals receive the training in combination with supporting tools (pocket card) and educational material (the ReNeWAL criteria and PowerPoint slides of the training if requested). Also, intervision moments are planned.
Study: NCT06730698

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06730750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986490
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986490
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986490
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986490
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986490
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days.
Study: NCT05400889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.
Study: NCT01240928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSK-2206
Description: Level 1: MK-2206 135mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Level 1: Exemestane - 25mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
Study: NCT06731387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical technical assistants supported medication dispensation on the hospital ward
Description: Pharmaceutical technical assistants (PTAs) visit the hospital ward for two hours in the morning or afternoon to dispense medications for admitted patients for the following day. Night nurses then complete any final additions or adjustments as needed.
Study: NCT05127824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous alpha-DC1/TBVA vaccine
Description: Dendritic cells (DC) are derived from autologous (the subject's own) mononuclear cells in the peripheral blood obtained from the PRBC. In this case, biologic product and biologic substance are the same. The vaccine will be manufactured in the HCC-IMPCL, under cGMP conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
Study: NCT05320198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-0974
Description: DISC-0974 is administered subcutaneously.
Study: NCT05223842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Promoting Positive Emotions (F-PPE)
Description: F-PPE is an 8-session dyadic intervention designed to enhance positive emotionality and buffer against the effects of stress on anhedonia in children. The intervention will be administered online through videoconferencing sessions with a clinician to mothers and their children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: Mothers assigned to the Written Information condition will receive email newsletters providing resources relevant to depression.